Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Influenza

Free Subscription Articles published in Arch Virol Retrieve available abstracts of 85 articles: HTML format

Single Articles

March 2026
1. DUTTA M, Sarmah N, Siddique AI, Borah P, et al
   Temporal trends and burden of influenza B virus lineages in Dibrugarh, Assam (2014-2025): predominance of Victoria with early circulation of Yamagata.
   Arch Virol. 2026;171:110.
   PubMed    
   
   
   February 2026
2. KOBAYASHI D, Hiono T, Adachi R, Igarashi M, et al
   Length and density of alpha2-3 sialyllactose-containing chains on glycopolymers determine receptor binding of avian influenza viruses.
   Arch Virol. 2026;171:100.
   PubMed    
   
   
   
3. PARK SH, Lee SH, Seo YR, Kim DJ, et al
   Evolution and spread of H8Nx avian influenza viruses from wild birds in East Asia, 2019-2024.
   Arch Virol. 2026;171:95.
   PubMed     Abstract available
   
   
   
4. NAVEED A
   The bovine mammary gland as a crucible for zoonotic influenza virus emergence: Receptor-mediated adaptation of HPAI H5N1 clade 2.3.4.4b.
   Arch Virol. 2026;171:89.
   PubMed    
   
   
   
5. LIM KS, Selvan ME, Ea CK, Teo CH, et al
   CircRNA expression profiling in H1N1-infected primary human tracheobronchial epithelial cells identifies candidate immune-related circRNAs validated in A549 cells.
   Arch Virol. 2026;171:85.
   PubMed     Abstract available
   
   
   
6. JAMAL Z, Haider SA, Humayun F, Ali Q, et al
   Genomic surveillance of Influenza, SARS-CoV-2, and RSV in patients from Islamabad and Rawalpindi, Pakistan: a 2023-24 perspective.
   Arch Virol. 2026;171:78.
   PubMed    
   
   
   
7. SHILOVA NV, Yermolaeva DR, Nokel AY, Chinarev AA, et al
   Antibody-free detection of influenza viruses on a microarray to study their receptor specificity.
   Arch Virol. 2026;171:75.
   PubMed    
   
   
   January 2026
8. LAI QR, Chen W, Yu GF, Guo YJ, et al
   Molecular epidemiology and clinical characteristics of human adenovirus in children in Hangzhou (2022-2023).
   Arch Virol. 2026;171:60.
   PubMed     Abstract available
   
   
   
9. YAN Y, Pan Z, Mao L, Niu P, et al
   Genome surveillance of SARS-CoV-2 Omicron XBB subvariants in Wuhan in June 2023.
   Arch Virol. 2026;171:38.
   PubMed     Abstract available
   
   
   December 2025
10. BEDAIR NM, Sakr MA, Mourad A, Eissa N, et al
    Genetic characterization of highly pathogenic avian influenza A/H5N8 virus isolated from commercial poultry farms in Egypt reveals zoonotic potential.
    Arch Virol. 2025;171:29.
    PubMed     Abstract available
    
    
    November 2025
11. WANG P, Fu J, Wu H, Zhu L, et al
    Amino acid substitutions associated with adaptation of novel H10N3 and H10N5 avian influenza viruses to mice.
    Arch Virol. 2025;170:242.
    PubMed    
    
    
    October 2025
12. YIN Y, Chen J, Chen S, Huang J, et al
    The SARS-CoV-2 N protein disrupts G3BP1 function and alters lipid metabolism in COVID-19 pathogenesis.
    Arch Virol. 2025;170:237.
    PubMed     Abstract available
    
    
    September 2025
13. PUENPA J, Dara S, Vichaiwattana P, Aeemjinda R, et al
    Seasonal dynamics and genetic diversity of human rhinoviruses in patients with acute respiratory infection in Bangkok in 2024.
    Arch Virol. 2025;170:208.
    PubMed     Abstract available
    
    
    August 2025
14. HU Y, Hu C, Su J, Zhu B, et al
    Two cross-neutralizing antibodies isolated from a COVID-19 convalescent via single B cell sorting.
    Arch Virol. 2025;170:199.
    PubMed     Abstract available
    
    
    
15. FERNANDEZ-ROJAS MA, Salazar AM, Ostrosky-Wegman P, Flisser A, et al
    A feedback loop between DNA damage, genomic instability, and cytoplasmic DNA sensing contributes to cytokine production in COVID-19.
    Arch Virol. 2025;170:192.
    PubMed     Abstract available
    
    
    July 2025
16. NEMOTO M, Kawanishi N, Kambayashi Y, Bannai H, et al
    Growth properties of recombinant equine influenza viruses with different backbones generated by reverse genetics in embryonated chicken eggs.
    Arch Virol. 2025;170:181.
    PubMed     Abstract available
    
    
    June 2025
17. LU Y, Ni J, Huang S, Guo Y, et al
    Epidemiological characteristics of human parainfluenza virus infections and phylogenetic analysis of human parainfluenza virus type 3 isolated from children with respiratory tract infections from 2020 to 2022 in Zhejiang, China.
    Arch Virol. 2025;170:157.
    PubMed     Abstract available
    
    
    
18. JIN H, Cho YR, Jung YT
    Single-particle quantification of SARS-CoV-2 virus-like particles using flow virometry.
    Arch Virol. 2025;170:149.
    PubMed     Abstract available
    
    
    May 2025
19. LIU X
    ACE2, a therapeutic target of COVID-19, needs to be treated with caution.
    Arch Virol. 2025;170:143.
    PubMed     Abstract available
    
    
    
20. CHEN T, Xu W, Duan P, Jiang S, et al
    MF59-like adjuvant containing yeast-derived squalene enhances the humoral immune response to cell-derived influenza vaccine.
    Arch Virol. 2025;170:134.
    PubMed     Abstract available
    
    
    April 2025
21. SVYATCHENKO SV, Boldyrev ND, Panova AS, Kolosova NP, et al
    Seroprevalence of anti-influenza antibodies in humans and characterization of seasonal influenza viruses isolated in Russia during the 2023-2024 flu season.
    Arch Virol. 2025;170:118.
    PubMed     Abstract available
    
    
    
22. HUANG Z, Zhang R, Yao D, Fu H, et al
    Avian influenza A(H5N6) virus detected during live-poultry market surveillance linked to a human infection in Changsha, China, from 2020 to 2023.
    Arch Virol. 2025;170:96.
    PubMed     Abstract available
    
    
    March 2025
23. YE QY, Jiang ZT, Jiang Y, Cai JW, et al
    Effectiveness of inactivated COVID-19 vaccine against symptom severity in hospitalized COVID-19 patients infected with the Omicron variant.
    Arch Virol. 2025;170:88.
    PubMed     Abstract available
    
    
    
24. ZHANG H, Ouyang S, Qu Y, Li Z, et al
    Humoral immune response characteristics of vulnerable populations against SARS-CoV-2 strains EG.5 and JN.1 after infection with strains BA.5 and XBB.
    Arch Virol. 2025;170:82.
    PubMed     Abstract available
    
    
    January 2025
25. SAKUMA S, Mine J, Uchida Y, Kumagai A, et al
    Long-term immune responses induced by low-dose infection with high pathogenicity avian influenza viruses can protect mallards from reinfection with a heterologous strain.
    Arch Virol. 2025;170:33.
    PubMed     Abstract available
    
    
    
26. ARVIA R, Rocca A, Casciato B, Stincarelli MA, et al
    High-resolution melting analysis for detection of nucleotide mutation markers in the polymerase-acidic (PA) gene of influenza virus that are associated with baloxavir marboxil resistance.
    Arch Virol. 2025;170:29.
    PubMed     Abstract available
    
    
    
27. ASHRAF MA, Raza MA, Imran A, Amjad MN, et al
    Next-generation vaccines for influenza B virus: advancements and challenges.
    Arch Virol. 2025;170:25.
    PubMed     Abstract available
    
    
    
28. REHMAN Z, Edington K, Jamal Z, Kritz-Wilson A, et al
    The introduction of the SARS-CoV-2 BA.4 lineage into Pakistan.
    Arch Virol. 2025;170:26.
    PubMed     Abstract available
    
    
    December 2024
29. ZALI M, Sadat Larijani M, Bavand A, Moradi L, et al
    Circulatory microRNAs as potential biomarkers for different aspects of COVID-19.
    Arch Virol. 2024;170:8.
    PubMed     Abstract available
    
    
    
30. NAVARRO-LOPEZ R, Valdez-Gomez HE, Zalapa-Hernandez M, Solis-Hernandez M, et al
    An epizootic of highly pathogenic avian influenza virus H7N3 in a Mexican ecological reserve.
    Arch Virol. 2024;170:6.
    PubMed     Abstract available
    
    
    
31. GUNASEKARA E, Hair-Bejo M, Aini I, Omar AR, et al
    Molecular characterisation of novel reassortants of the G57 genotype of low-pathogenic avian influenza H9N2 virus isolated from poultry farms in Malaysia.
    Arch Virol. 2024;170:3.
    PubMed     Abstract available
    
    
    
32. MISHRA S, Pandey A, Verma J, Rajala MS, et al
    Analysis of the interaction of influenza a virus nucleoprotein with host cell nucleolin.
    Arch Virol. 2024;170:1.
    PubMed     Abstract available
    
    
    November 2024
33. ZHANG WX, Zou L, Cui Y, Zhou Y, et al
    Molecular epidemiology of herpangina in the subcenter of Beijing, China: a surveillance study during 2021-2022.
    Arch Virol. 2024;169:245.
    PubMed     Abstract available
    
    
    October 2024
34. WU YJ, Feng WW, Wu ZL, Zhang YY, et al
    Prim-O-glucosylcimifugin alleviates influenza virus-induced pneumonia in mice by inhibiting the TGF-beta1/PI3KCD/MSK2/RELA signalling pathway.
    Arch Virol. 2024;169:232.
    PubMed     Abstract available
    
    
    
35. LI F, Zhu Y, Li Q, Guan X, et al
    Genomic characteristics of human respiratory syncytial virus from children in China during 2017-2020.
    Arch Virol. 2024;169:219.
    PubMed     Abstract available
    
    
    
36. NIYOMDECHA N, Boonarkart C, Thongon S, Auewarakul P, et al
    Comparative study of the propagation and plaque titration conditions for human coronavirus OC43 as a surrogate for SARS-CoV-2.
    Arch Virol. 2024;169:214.
    PubMed     Abstract available
    
    
    September 2024
37. ICHIKAWA T, Hiono T, Okamatsu M, Maruyama J, et al
    Hemagglutinin and neuraminidase of a non-pathogenic H7N7 avian influenza virus coevolved during the acquisition of intranasal pathogenicity in chickens.
    Arch Virol. 2024;169:207.
    PubMed     Abstract available
    
    
    
38. WANG H, Wang J, Zhang J, Song J, et al
    Graphene oxide nanoparticles inhibit H9N2 influenza A virus infectivity by destroying viral coat proteins.
    Arch Virol. 2024;169:192.
    PubMed     Abstract available
    
    
    July 2024
39. FANG F, Wang B, Lu X, Wang L, et al
    miR-126a-5p inhibits H1N1-induced inflammation and matrix protease secretion in lung fibroblasts by targeting ADAMTS-4.
    Arch Virol. 2024;169:164.
    PubMed     Abstract available
    
    
    May 2024
40. HE L, Cao J, Xie X, Zhang Y, et al
    Effects and mechanism of Qingke Pingchuan granules against influenza virus infection.
    Arch Virol. 2024;169:130.
    PubMed     Abstract available
    
    
    
41. ASADIPOOYA K, Asadipooya A, Adatorwovor R
    Combination of spironolactone and DPP-4 inhibitors for treatment of SARS-CoV-2 infection: a literature review.
    Arch Virol. 2024;169:122.
    PubMed     Abstract available
    
    
    April 2024
42. TARE DS, Keng SS, Walimbe AM, Pawar SD, et al
    Phylogeography and gene pool analysis of highly pathogenic avian influenza H5N1 viruses reported in India from 2006 to 2021.
    Arch Virol. 2024;169:111.
    PubMed     Abstract available
    
    
    
43. YOUSFI FZE, Haroun AE, Nebhani C, Belayachi J, et al
    Prevalence of the protective OAS1 rs10774671-G allele against severe COVID-19 in Moroccans: implications for a North African Neanderthal connection.
    Arch Virol. 2024;169:109.
    PubMed     Abstract available
    
    
    
44. HAIDER SA, Jamal Z, Tahir F, Salman M, et al
    Genomic characterization of human respiratory syncytial virus circulating in Islamabad, Pakistan, during an outbreak in 2022-2023.
    Arch Virol. 2024;169:106.
    PubMed     Abstract available
    
    
    
45. BEDAIR NM, Sakr MA, Mourad A, Eissa N, et al
    Molecular characterization of the whole genome of H9N2 avian influenza virus isolated from Egyptian poultry farms.
    Arch Virol. 2024;169:99.
    PubMed     Abstract available
    
    
    
46. KUTKAT O, Gomaa M, Aboulhoda BE, Moatasim Y, et al
    Genetic and virological characteristics of a reassortant avian influenza A H6N1 virus isolated from wild birds at a live-bird market in Egypt.
    Arch Virol. 2024;169:95.
    PubMed     Abstract available
    
    
    
47. TRAN DH, Do HDK, Tran HT, Pham TNM, et al
    Rapid identification of SARS-CoV-2 strains via isothermal enzymatic recombinase amplification and nanopore sequencing.
    Arch Virol. 2024;169:87.
    PubMed     Abstract available
    
    
    March 2024
48. LI X, Ding G, Li S, Liu C, et al
    Proteomic characteristics of the treatment trajectory of patients with COVID-19.
    Arch Virol. 2024;169:84.
    PubMed     Abstract available
    
    
    
49. YUAN J, Pan J, Zhang X, Gao R, et al
    TRIM21 reduces H1N1-induced inflammation and apoptosis by regulating the TBK1-IRF3 signaling pathway in A549 cells.
    Arch Virol. 2024;169:74.
    PubMed     Abstract available
    
    
    February 2024
50. KIM HJ, Park JG, Moon KS, Jung SB, et al
    Identification and characterization of a marine bacterium extract from Mameliella sp. M20D2D8 with antiviral effects against influenza A and B viruses.
    Arch Virol. 2024;169:41.
    PubMed     Abstract available
    
    
    January 2024
51. ZHUANG J, Yan Z, Zhou T, Li Y, et al
    The role of receptors in the cross-species spread of coronaviruses infecting humans and pigs.
    Arch Virol. 2024;169:35.
    PubMed     Abstract available
    
    
    
52. WANG Y, Liu Y, Wang Y, Mai H, et al
    Clinical characteristics of outpatients with influenza-B-associated pneumonia and molecular evolution of influenza B virus in Beijing, China, during the 2021-2022 influenza season.
    Arch Virol. 2024;169:30.
    PubMed     Abstract available
    
    
    
53. TANIGUCHI K, Noshi T, Omoto S, Sato A, et al
    The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
    Arch Virol. 2024;169:29.
    PubMed     Abstract available
    
    
    
54. LIU H, Wang J, Li S, Sun Y, et al
    The unfolded protein response pathway as a possible link in the pathogenesis of COVID-19 and sepsis.
    Arch Virol. 2024;169:20.
    PubMed     Abstract available
    
    
    November 2023
55. JAMSHIDINIA N, Saadatpour F, Arefian E, Mohammadipanah F, et al
    Augmented antiviral activity of chlorhexidine gluconate on herpes simplex virus type 1, H1N1 influenza A virus, and adenovirus in combination with salicylic acid.
    Arch Virol. 2023;168:302.
    PubMed     Abstract available
    
    
    
56. ABDUL-KAREEM HH, Al-Maqtoofi MY, Burghal AA
    Impact of COVID-19 vaccination on saliva immune barriers: IgA, lysozyme, and lactoferrin.
    Arch Virol. 2023;168:293.
    PubMed     Abstract available
    
    
    
57. WAN L, Li L, Zhang H, Liu C, et al
    The changing pattern of common respiratory viruses among children from 2018 to 2021 in Wuhan, China.
    Arch Virol. 2023;168:291.
    PubMed     Abstract available
    
    
    October 2023
58. MOON SH, Na W, Shin S, Kim H, et al
    Evidence for the circulation of genotype 4 Eurasian avian-like lineage swine H1N1 influenza A viruses on Korean swine farms, obtained using a newly developed one-step multiplex RT-qPCR assay.
    Arch Virol. 2023;168:267.
    PubMed     Abstract available
    
    
    September 2023
59. MESEKO C, Ameji NO, Kumar B, Culhane M, et al
    Rational approach to vaccination against highly pathogenic avian influenza in Nigeria: a scientific perspective and global best practice.
    Arch Virol. 2023;168:263.
    PubMed     Abstract available
    
    
    
60. DAVE B, Shah KC, Chorawala MR, Shah N, et al
    Molnupiravir: an antiviral drug against COVID-19.
    Arch Virol. 2023;168:252.
    PubMed     Abstract available
    
    
    
61. DEGIUSEPPE JI, Martelli A, Barrios Mathieur C, Stupka JA, et al
    Genetic diversity of rotavirus A in Argentina during 2019-2022: detection of G6 strains and insights regarding its dissemination.
    Arch Virol. 2023;168:251.
    PubMed     Abstract available
    
    
    August 2023
62. TRIPATHY AS, Wagh P, Akolkar K, Walimbe AM, et al
    Association of inhibitory NKG2A and activating NKG2D natural killer cell receptor genes with resistance to SARS-CoV-2 infection in a western Indian population.
    Arch Virol. 2023;168:237.
    PubMed     Abstract available
    
    
    
63. PHAM NTK, Khamrin P, Shimizu-Onda Y, Hoque SA, et al
    Genetic diversity and declining norovirus prevalence in infants and children during Japan's COVID-19 pandemic: a three-year molecular surveillance.
    Arch Virol. 2023;168:231.
    PubMed     Abstract available
    
    
    
64. ZHOU Y, Chen Z
    Mpox: a review of laboratory detection techniques.
    Arch Virol. 2023;168:221.
    PubMed     Abstract available
    
    
    July 2023
65. MA H, Ren S, Meng Q, Su B, et al
    Role of Tim-3 in COVID-19: a potential biomarker and therapeutic target.
    Arch Virol. 2023;168:213.
    PubMed     Abstract available
    
    
    June 2023
66. FAYYAD-KAZAN M, Makki R, Homsi ME, Samadi A, et al
    Circulating microRNA profile in response to remdesivir treatment in coronavirus disease 2019 (COVID-19) patients.
    Arch Virol. 2023;168:194.
    PubMed     Abstract available
    
    
    
67. LOBAINA Y, Chen R, Suzarte E, Ai P, et al
    Broad humoral immunity generated in mice by a formulation composed of two antigens from the Delta variant of SARS-CoV-2.
    Arch Virol. 2023;168:190.
    PubMed     Abstract available
    
    
    
68. BHANOTHU V, Munne K, Pande S, Singh P, et al
    The dynamics of SARS-CoV-2 infection in unvaccinated and vaccinated populations in Mumbai, India, between 28 December 2020 and 30 August 2021.
    Arch Virol. 2023;168:188.
    PubMed     Abstract available
    
    
    
69. SENTHILAZHAGAN K, Sakthimani S, Kallanja D, Venkataraman S, et al
    SARS-CoV-2: analysis of the effects of mutations in non-structural proteins.
    Arch Virol. 2023;168:186.
    PubMed     Abstract available
    
    
    
70. UPADHYAY R, Tiwari KN
    The antiviral potential of Phyllanthus species: a systematic review.
    Arch Virol. 2023;168:177.
    PubMed     Abstract available
    
    
    
71. VALDES-LOPEZ JF, Urcuqui-Inchima S
    Antiviral response and immunopathogenesis of interleukin 27 in COVID-19.
    Arch Virol. 2023;168:178.
    PubMed     Abstract available
    
    
    
72. PATTANAIK A, Bhandarkar B S, Lodha L, Marate S, et al
    SARS-CoV-2 and the nervous system: current perspectives.
    Arch Virol. 2023;168:171.
    PubMed     Abstract available
    
    
    May 2023
73. ZHANG Y, Wang J, Xie Y, Cao X, et al
    Epidemiological characteristics of patients from fever clinics during the COVID-19 epidemic in 2022 in Shanghai, China.
    Arch Virol. 2023;168:164.
    PubMed     Abstract available
    
    
    
74. SUHARSONO H, Mahardika BK, Sudipa PH, Sari TK, et al
    Consensus insertion/deletions and amino acid variations of all coding and noncoding regions of the SARS-CoV-2 Omicron clades, including the XBB and BQ.1 lineages.
    Arch Virol. 2023;168:156.
    PubMed     Abstract available
    
    
    
75. TATSI EB, Koukou DM, Dellis C, Dourdouna MM, et al
    Epidemiological study of unusual rotavirus strains and molecular characterization of emerging P[14] strains isolated from children with acute gastroenteritis during a 15-year period.
    Arch Virol. 2023;168:149.
    PubMed     Abstract available
    
    
    April 2023
76. MANSOURABADI AH, Aghamajidi A, Dorfaki M, Keshavarz F, et al
    B lymphocytes in COVID-19: a tale of harmony and discordance.
    Arch Virol. 2023;168:148.
    PubMed     Abstract available
    
    
    
77. DA COSTA MA, de Almeida RPA, Ponde RAA
    Clinical-laboratory profile of children and adolescents with multisystem inflammatory syndrome temporarily associated with COVID-19 in Goias, Brazil.
    Arch Virol. 2023;168:142.
    PubMed     Abstract available
    
    
    
78. KAWABATA K, Sato Y, Kubo T, Tokumura A, et al
    Phospholipid analysis of two influenza A virus-infected cell lines differing in their viral replication kinetics.
    Arch Virol. 2023;168:132.
    PubMed     Abstract available
    
    
    March 2023
79. MARTINS M, do Nascimento GM, Conforti A, Noll JCG, et al
    A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets.
    Arch Virol. 2023;168:124.
    PubMed     Abstract available
    
    
    
80. MAO L, Chen Y, Gu J, Zhao Y, et al
    Roles and mechanisms of exosomal microRNAs in viral infections.
    Arch Virol. 2023;168:121.
    PubMed     Abstract available
    
    
    
81. SHI T, Zhao X, Zhang X, Meng L, et al
    Immediate and long-term changes in the epidemiology, infection spectrum, and clinical characteristics of viral and bacterial respiratory infections in Western China after the COVID-19 outbreak: a modeling study.
    Arch Virol. 2023;168:120.
    PubMed     Abstract available
    
    
    
82. ZABIHI RIZI F, Ghorbani A, Zahtab P, Darbaghshahi NN, et al
    TYK2 single-nucleotide variants associated with the severity of COVID-19 disease.
    Arch Virol. 2023;168:119.
    PubMed     Abstract available
    
    
    
83. BORKAKOTI R, Karikalan M, Nehul SK, Jogi HR, et al
    A retrospective study showing a high rate of seropositivity against SARS-CoV-2 in wild felines in India.
    Arch Virol. 2023;168:109.
    PubMed     Abstract available
    
    
    February 2023
84. FALCON-CAMA V, Montero-Gonzalez T, Acosta-Medina EF, Guillen-Nieto G, et al
    Evidence of SARS-CoV-2 infection in postmortem lung, kidney, and liver samples, revealing cellular targets involved in COVID-19 pathogenesis.
    Arch Virol. 2023;168:96.
    PubMed     Abstract available
    
    
    
85. SALEM S, Mosaad R, Lotfy R, Elbadry M, et al
    Altered expression of DNA methyltransferases and methylation status of the TLR4 and TNF-alpha promoters in COVID-19.
    Arch Virol. 2023;168:95.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum